" class="no-js "lang="en-US"> Axogen Appoints Jens Schroeder Kemp as Chief Marketing Officer
Thursday, March 23, 2023

Axogen Appoints Jens Schroeder Kemp as Chief Marketing Officer

Axogen, a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Jens Schroeder Kemp to the newly created role of Chief Marketing Officer. Kemp brings more than 20 years of strategic marketing, sales, and business development experience in high-growing medical technology. As a member of the Axogen executive leadership team, Kemp will report directly to Karen Zaderej, Chairman, CEO and President, and will oversee the development and execution of the company’s marketing strategies.

“I am thrilled to welcome Jens to Axogen. His extensive strategic marketing experience and track record of growth is an ideal addition to our team,” commented Ms. Zaderej. “We look forward to leveraging his experience combined with the magnitude and strength of our clinical portfolio to drive increased surgeon adoption and support continued innovation of our nerve repair solutions.”

Mr. Kemp most recently served as Vice President of Marketing for Ambu Inc, where he led Ambu’s marketing efforts to create the single use endoscopy market across multiple clinical applications. Following Ambu’s acquisition of King Systems in 2012, Mr. Kemp developed and scaled the US marketing function with new capabilities in health economics and market access, market development and digital marketing. Across more than 15 years at Ambu, he had multiple roles in business development and marketing, and served as a member of the Global Management Team. Prior to Ambu, Mr. Kemp was a management consultant at PERA (Production and Engineering Research Association), where his role included sales, marketing, and innovation strategies for medical device and renewable energy products. Previously, he was co-founder of an artificial intelligence decision support software company Mindgroup ApS.

“I am very pleased to be joining Axogen at this exciting time,” said Mr. Kemp. “Axogen’s portfolio offers clinical benefits to patients and healthcare providers, and I look forward to engaging with surgeons as we continue to innovate and change the standard of care for patients with nerve injuries.”

Mr. Kemp has a bachelor’s degree in business administration, and a master’s degree in international marketing and management, both from Copenhagen Business School.

  1. OliX Pharmaceuticals Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia Read more
  2. Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer Read more
  3. BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases Read more
  4. Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome Read more
  5. Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application Read more